Briefing
Circulating KIM-1 and ctDNA as prognostic markers in oligometastatic clear cell renal cell carcinoma (ccRCC): The K-COMPASS model.
ASCO GU 2026 abstract 537: among 112 patients, baseline and 3-month KIM-1 and ctDNA MRD were each associated with STFS in univariable and multivariable analyses; K-COMPASS (baseline KIM-1, baseline ctDNA MRD, and four clinical variables) had C-index 0.76 and calibration slope 1.
- n: 112 patients with KIM-1 measurements; median baseline KIM-1 127.0 pg/mL (IQR 71.5–228.0)
- Assay: Personalized ctDNA detection panels (≤2000 somatic variants) from tumor whole-genome sequencing (Myriad Genetics); plasma KIM-1
ASCO Genitourinary Cancers Symposium 2026, Abstract 537 2026